Drug Profile
MTR 105 - Biodexa Pharmaceuticals
Alternative Names: MTR105 - Biodexa PharmaceuticalsLatest Information Update: 08 Sep 2023
Price :
$50
*
At a glance
- Originator Midatech
- Developer Biodexa Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Squamous cell cancer
Most Recent Events
- 08 Sep 2023 Discontinued - Preclinical for Squamous cell cancer in United Kingdom (unspecified route)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Squamous-cell-cancer in United Kingdom
- 11 May 2016 Preclinical trials in Squamous cell cancer in United Kingdom (unspecified route)